{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:45:42Z","timestamp":1766087142120},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11920-016-0730-1","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T08:05:43Z","timestamp":1473840343000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current Understanding of Psychosis in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"18","author":[{"given":"Oluwadamilola O.","family":"Ojo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,14]]},"reference":[{"issue":"3","key":"730_CR1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.59.3.408","volume":"59","author":"T Witjas","year":"2002","unstructured":"Witjas T et al. Nonmotor fluctuations in Parkinson\u2019s disease: frequent and disabling. Neurology. 2002;59(3):408\u201313.","journal-title":"Neurology"},{"issue":"1","key":"730_CR2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mds.10010","volume":"17","author":"Global Parkinson\u2019s disease Survey Steering Committee","year":"2002","unstructured":"Global Parkinson\u2019s disease Survey Steering Committee. Factors impacting on quality of life in Parkinson\u2019s disease: results from an international survey. Mov Disord. 2002;17(1):60\u20137.","journal-title":"Mov Disord."},{"issue":"4","key":"730_CR3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","volume":"27","author":"JH Friedman","year":"2013","unstructured":"Friedman JH. Parkinson\u2019s disease psychosis: update. Behav Neurol. 2013;27(4):469\u201377. Updated review article highlighting the epidemiology, clinical features, diagnosis, differential diagnoses, pathophysiology and management of psychosis in Parkinson\u2019s disease.","journal-title":"Behav Neurol"},{"issue":"1","key":"730_CR4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","volume":"12","author":"A Schrag","year":"2006","unstructured":"Schrag A et al. Caregiver-burden in Parkinson\u2019s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006;12(1):35\u201341.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"730_CR5","first-page":"135","volume":"28","author":"DR Lee","year":"2012","unstructured":"Lee DR et al. Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms. Int J Geriatr Psychiatry. 2012;28(2):135\u201341.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"15","key":"730_CR6","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/mds.23394","volume":"25","author":"DA Gallagher","year":"2010","unstructured":"Gallagher DA, Lees AJ, Schrag A. What are the most important non-motor symptoms in patients with Parkinson\u2019s disease and are we missing them? Mov Disord. 2010;25(15):2493\u2013500.","journal-title":"Mov Disord"},{"issue":"10","key":"730_CR7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.parkreldis.2009.05.011","volume":"15","author":"Z Qin","year":"2009","unstructured":"Qin Z et al. Health-related quality of life in early Parkinson\u2019s disease: impact of motor and non-motor symptoms: results from Chinese levodopa exposed cohort. Park Rel Disord. 2009;15(10):767\u201371.","journal-title":"Park Rel Disord"},{"issue":"11","key":"730_CR8","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"CG Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology. 1993;43(11):2227\u20139.","journal-title":"Neurology"},{"issue":"8","key":"730_CR9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","volume":"48","author":"D Aarsland","year":"2000","unstructured":"Aarsland D et al. Predictors for nursing home placement in Parkinson\u2019s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48(8):938\u201342.","journal-title":"J Am Geriatr Soc"},{"key":"730_CR10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","volume":"45","author":"CG Goetz","year":"1995","unstructured":"Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson\u2019s disease. Neurology. 1995;45:669\u201371.","journal-title":"Neurology."},{"key":"730_CR11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","volume":"63","author":"L Marsh","year":"2004","unstructured":"Marsh L et al. Psychiatric comorbidities in patients with Parkinson\u2019s disease and psychosis. Neurology. 2004;63:293\u2013300.","journal-title":"Neurology."},{"issue":"1","key":"730_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000191325.31068.c4","volume":"66","author":"G F\u00e9nelon","year":"2006","unstructured":"F\u00e9nelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the pre-levodopa era. Neurology. 2006;66(1):93\u20138.","journal-title":"Neurology"},{"issue":"4","key":"730_CR13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00019052-200108000-00011","volume":"14","author":"EC Wolters","year":"2001","unstructured":"Wolters EC, Berendse HW. Management of psychosis in Parkinson\u2019s disease. Curr Opin Neurol. 2001;14(4):499\u2013504.","journal-title":"Curr Opin Neurol"},{"issue":"3Suppl 4","key":"730_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/S1092852900017296","volume":"13","author":"LB Zahodne","year":"2008","unstructured":"Zahodne LB, Fernandez HH. Course, prognosis, and management of psychosis in Parkinson\u2019s disease: are current treatments really effective? CNS Spectr. 2008;13(3Suppl 4):26\u201333.","journal-title":"CNS Spectr"},{"issue":"Pt 4","key":"730_CR15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G Fenelon","year":"2000","unstructured":"Fenelon G et al. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733\u201345.","journal-title":"Brain"},{"key":"730_CR16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina B et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NIND, NIMH work group. Mov Disord. 2007;22:1061\u20138.","journal-title":"Mov Disord."},{"key":"730_CR17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"S Holroyd","year":"2001","unstructured":"Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2001;70:734\u20138.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"730_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.JGP.0000192480.89813.80","volume":"14","author":"UP Mosimann","year":"2006","unstructured":"Mosimann UP et al. Characteristics of visual hallucinations in Parkinson\u2019s disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2006;14:153\u201360.","journal-title":"Am J Geriatr Psychiatry."},{"key":"730_CR19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland D et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16:528\u201336.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"3","key":"730_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/S11.940-013-0281-2","volume":"16","author":"JG Goldman","year":"2014","unstructured":"Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson\u2019s disease. Curr Treat Options Neurol. 2014;16(3):281. doi: 10.1007\/S11.940-013-0281-2 .","journal-title":"Curr Treat Options Neurol"},{"key":"730_CR21","doi-asserted-by":"crossref","unstructured":"Fenelon G, Alves G. Epidemiology of psychosis in Parkinson\u2019s disease. J Neurol Sci. 2010;289:12\u20137. Review focusing on the epidemiology of psychosis in Parkinson\u2019s disease; highlighting methodological issues contributing to variability in prevalence estimates and also identifies areas where data is lacking and more research\/longitudinal studies required\u2014incidence and associated risk factors.","DOI":"10.1016\/j.jns.2009.08.014"},{"key":"730_CR22","doi-asserted-by":"crossref","unstructured":"Fenelon G et al. The changing face of Parkinson\u2019s disease associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763\u20136. Cross-sectional outpatient study that evaluated the prevalence of Parkinson\u2019s disease psychosis using new criteria established by NINDS-NIMH. Study confirmed an increase in prevalence with application of the new criteria.","DOI":"10.1002\/mds.22839"},{"issue":"2","key":"730_CR23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/JGP.0b013e31821f1b41","volume":"20","author":"J Mack","year":"2012","unstructured":"Mack J et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012;20(2):123\u201332.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"730_CR24","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.25003","volume":"27","author":"AH Lee","year":"2012","unstructured":"Lee AH, Weintraub D. Psychosis in Parkinson\u2019s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858\u201363.","journal-title":"Mov Disord"},{"key":"730_CR25","doi-asserted-by":"crossref","unstructured":"Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson\u2019s disease in Tanzania. Parkinsonism Relat Disord. 2009;15(6):457\u201360. Community-based study that revealed the presence of non-motor symptoms at varying stages of Parkinson\u2019s disease in an African community. Study added to the body of evidence highlighting the presence of symptomatology of Parkinson\u2019s disease psychosis in treatment-na\u00efve and non-demented Parkinson\u2019s disease patients.","DOI":"10.1016\/j.parkreldis.2008.11.013"},{"key":"730_CR26","first-page":"675630","volume":"2011","author":"JG Goldman","year":"2011","unstructured":"Goldman JG. New thoughts on thought disorders in Parkinson\u2019s disease: review of current research strategies and challenges. Parkinsons Dis. 2011;2011:675630.","journal-title":"Parkinsons Dis."},{"key":"730_CR27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002826-199108000-00001","volume":"14","author":"JH Friedman","year":"1991","unstructured":"Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol. 1991;14:283\u201395.","journal-title":"Clin Neuropharmacol."},{"key":"730_CR28","first-page":"115","volume":"65","author":"SA Factor","year":"1995","unstructured":"Factor SA et al. Parkinson\u2019s disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115\u201338.","journal-title":"Adv Neurol."},{"issue":"5","key":"730_CR29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","volume":"56","author":"D Aarsland","year":"1999","unstructured":"Aarsland D et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson\u2019s disease: a community-based study. Arch Neurol. 1999;56(5):595\u2013601.","journal-title":"Arch Neurol"},{"issue":"10 \u2013 11","key":"730_CR30","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00702-004-0209-9","volume":"111","author":"D Merims","year":"2004","unstructured":"Merims D et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson\u2019s disease. J Neural Transm. 2004;111(10 \u2013 11):1447\u201353.","journal-title":"J Neural Transm"},{"key":"730_CR31","first-page":"136","volume":"12","author":"CM Tanner","year":"1983","unstructured":"Tanner CM et al. Hallucinations in Parkinson\u2019s disease: a population study. Ann Neurol. 1983;12:136.","journal-title":"Ann Neurol."},{"key":"730_CR32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","volume":"23","author":"JU Postuma","year":"1975","unstructured":"Postuma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc. 1975;23:212\u20135.","journal-title":"J Am Geriatr Soc."},{"key":"730_CR33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0278-5846(96)00158-3","volume":"21","author":"BY Glenthoj","year":"1997","unstructured":"Glenthoj BY, Hemmigsen R. Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21:23\u201346.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"8","key":"730_CR34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","volume":"25","author":"LB Zahodne","year":"2008","unstructured":"Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson\u2019s disease: a review. Drugs Aging. 2008;25(8):665\u201382.","journal-title":"Drugs Aging"},{"key":"730_CR35","doi-asserted-by":"crossref","first-page":"III\/22","DOI":"10.1007\/PL00007822","volume":"Suppl 3","author":"EC Wolters","year":"2001","unstructured":"Wolters EC. Intrinsic and extrinsic psychosis in Parkinson\u2019s disease. J Neurol. 2001;Suppl 3:III\/22\u20137.","journal-title":"J Neurol"},{"issue":"9","key":"730_CR36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.parkreldis.2010.05.004","volume":"16","author":"JH Friedman","year":"2010","unstructured":"Friedman JH. Parkinson\u2019s disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010;16(9):553\u201360.","journal-title":"Parkinsonism Relat Disord"},{"key":"730_CR37","doi-asserted-by":"crossref","unstructured":"Kurita A et al. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord. 2010;25(2):167\u201371. Neurophysiology study of the pathophysiology of visual hallucinations in dementia with Lewy Bodies and Parkinson\u2019s disease dementia.","DOI":"10.1002\/mds.22919"},{"key":"730_CR38","doi-asserted-by":"crossref","unstructured":"Ibarretze-Bilbao N, et al. Differential progression of brain atrophy in Parkinson\u2019s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry. 2010;81(6):650\u20137.","DOI":"10.1136\/jnnp.2009.179655"},{"key":"730_CR39","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1093\/brain\/awp223","volume":"132","author":"AM Meppelink","year":"2009","unstructured":"Meppelink AM et al. Impaired visual processing preceding image recognition in Parkinson\u2019s disease patient with visual hallucinations. Brain. 2009;132:2980\u201393.","journal-title":"Brain."},{"key":"730_CR40","first-page":"289","volume":"21","author":"NJ Diedrich","year":"1998","unstructured":"Diedrich NJ et al. Poor visual discrimination and visual hallucinations in Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21:289\u201395.","journal-title":"Clin Neuropharmacol."},{"issue":"2","key":"730_CR41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.55.2.281","volume":"55","author":"I Arnulf","year":"2000","unstructured":"Arnulf I et al. Hallucination, REMsleep, and Parkinson\u2019s disease: a medical hypothesis. Neurology. 2000;55(2):281.","journal-title":"Neurology"},{"key":"730_CR42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1017\/S1092852900017284","volume":"13","author":"G Fenelon","year":"2008","unstructured":"Fenelon G. Psychosis in Parkinson\u2019s disease: phenomenology, frequency, risk factors and current understanding of pathophysiologic mechanisms. CNS Spectr. 2008;13:18\u201325.","journal-title":"CNS Spectr."},{"key":"730_CR43","first-page":"393","volume":"45","author":"PJ Whitehouse","year":"1987","unstructured":"Whitehouse PJ. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson\u2019s disease and Alzheimer\u2019s disease. Adv neurol. 1987;45:393\u20137.","journal-title":"Adv neurol."},{"key":"730_CR44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.410400309","volume":"40","author":"DE Kuhl","year":"1996","unstructured":"Kuhl DE et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer\u2019s disease and Parkinson\u2019s disease. Ann Neurol. 1996;40:399\u2013410.","journal-title":"Ann Neurol."},{"key":"730_CR45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0166-2236(98)01361-7","volume":"22","author":"E Perry","year":"1999","unstructured":"Perry E et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends neurosci. 1999;22:273\u201380.","journal-title":"Trends neurosci."},{"key":"730_CR46","first-page":"125","volume":"5","author":"RC Mast Van der","year":"2000","unstructured":"Van der Mast RC, Fekkes D. Serotonin and amino acids: partners in delirium pathophysiology? Semin Clin Neuropsychiatry. 2000;5:125\u201331.","journal-title":"Semin Clin Neuropsychiatry."},{"key":"730_CR47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200326090-00004","volume":"26","author":"HH Fernandez","year":"2003","unstructured":"Fernandez HH, Trieschmann ME, Friedmann JH. The treatment of psychosis in Parkinson\u2019s disease: safety considerations. Drug Saf. 2003;26:643\u201359.","journal-title":"Drug Saf."},{"issue":"Pt2","key":"730_CR48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/brain\/awf033","volume":"125","author":"AJ Harding","year":"2002","unstructured":"Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(Pt2):391.","journal-title":"Brain"},{"key":"730_CR49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","volume":"50","author":"CJ Goetz","year":"1998","unstructured":"Goetz CJ et al. Intravenous levodopa in hallucinating Parkinson\u2019s disease: high-dose challenge does not precipitate hallucinations. Neurology. 1998;50:515\u20137.","journal-title":"Neurology."},{"key":"730_CR50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0891988704267457","volume":"17","author":"DP Wint","year":"2004","unstructured":"Wint DP, Okun MS, Fernandez HH. Psychosis in Parkinson\u2019s disease. J Geriatr Psychiatry Neurol. 2004;17:127\u201336.","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"730_CR51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09540260020002541","volume":"12","author":"MJ Henderson","year":"2000","unstructured":"Henderson MJ, Meilers JDC. Psychosis in Parkinson\u2019s disease: \u201cbetween a rock and a hard place.\u201d. Int Rev Psychiatry. 2000;12:319\u201334.","journal-title":"Int Rev Psychiatry"},{"key":"730_CR52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00023210-199911060-00005","volume":"11","author":"HH Fernandez","year":"1999","unstructured":"Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs. 1999;11:467\u201383.","journal-title":"CNS Drugs."},{"key":"730_CR53","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934\u201343.","journal-title":"JAMA."},{"key":"730_CR54","doi-asserted-by":"crossref","unstructured":"Weintraub D et al. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol. 2011;68:899\u2013904. Study comparing the use of antipsychotics in Parkinson\u2019s disease with psychosis with other dementia with psychosis. Study revealed rare prescription of clozapine and common prescription of high potency antipsychotics despite the FDA \u2018black box\u2019 warning.","DOI":"10.1001\/archneurol.2011.139"},{"key":"730_CR55","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","volume":"66","author":"JM Miyasaki","year":"2006","unstructured":"Miyasaki JM et al. Quality Substandards Committee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American academy of Neurology. Neurology. 2006;66:996\u20131002.","journal-title":"Neurology"},{"issue":"suppl 3","key":"730_CR56","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26 suppl 3:S42\u201380.","journal-title":"Mov Disord."},{"key":"730_CR57","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.135.6.669","volume":"135","author":"C Moskowitz","year":"1978","unstructured":"Moskowitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 1978;135:669\u201375.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"730_CR58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0897190011426556","volume":"24","author":"JH Friedman","year":"2011","unstructured":"Friedman JH. Atypical antipsychotic drugs in the treatment of Parkinson\u2019s disease. J Pharm Pract. 2011;24(6):534\u201340.","journal-title":"J Pharm Pract"},{"key":"730_CR59","doi-asserted-by":"crossref","unstructured":"Frieling H, et al. Treating dopamimetic psychosis in Parkinson\u2019s disease: structure review and meta-analysis. Eur Neuropsychopharmacol. 2007;17(3):165\u201371","DOI":"10.1016\/j.euroneuro.2006.08.007"},{"key":"730_CR60","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","year":"1999","unstructured":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. The Parkinson Study Group. N Engl J Med. 1999;340:757\u201363.","journal-title":"N Engl J Med"},{"key":"730_CR61","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"Clozapine in drug-induced psychosis in Parkinson\u2019s disease","year":"1999","unstructured":"Clozapine in drug-induced psychosis in Parkinson\u2019s disease. The French Clozapine Study Group. Lancet. 1999;353:2041\u20132.","journal-title":"Lancet"},{"key":"730_CR62","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.40.5.832","volume":"40","author":"EC Wolters","year":"1990","unstructured":"Wolters EC et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990;40:832\u20134.","journal-title":"Neurology."},{"key":"730_CR63","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.20051","volume":"19","author":"HH Fernandez","year":"2004","unstructured":"Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord. 2004;19:831\u20133.","journal-title":"Mov Disord."},{"key":"730_CR64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00002826-200301000-00003","volume":"26","author":"C Klein","year":"2003","unstructured":"Klein C et al. Clozapine in Parkinson\u2019s disease psychosis: 5-year follow-up review. Clin Neuropharmacol. 2003;26:8\u201311.","journal-title":"Clin Neuropharmacol."},{"key":"730_CR65","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"Suppl. 11","key":"730_CR66","first-page":"4","volume":"57","author":"E Richelson","year":"1996","unstructured":"Richelson E. Preclinical pharmacology of neuroleptics: new generation compounds. J Clin Psychiatry. 1996;57 Suppl 11:4\u201311.","journal-title":"J Clin Psychiatry"},{"key":"730_CR67","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","volume":"20","author":"WG Ondo","year":"2005","unstructured":"Ondo WG et al. Double-blind, placebo-controlled unforced titration parallel trial of quetiapine for dopaminergic induced hallucinations in Parkinson\u2019s disease. Mov Disord. 2005;20:958\u201363.","journal-title":"Mov Disord."},{"key":"730_CR68","first-page":"S46","volume":"20","author":"JM Rabey","year":"2005","unstructured":"Rabey JM et al. The effect of quetiapine in Parkinson\u2019s disease (PD) psychotic patients: a double-blind parallel study of 3 months duration. Mov Disord. 2005;20:S46.","journal-title":"Mov Disord"},{"key":"730_CR69","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3109\/00207450903222758","volume":"119","author":"HH Fernandez","year":"2009","unstructured":"Fernandez HH et al. Quetiapine improves visual hallucinations in Parkinson\u2019s disease but not through normalization of sleep architecture: results from a double-blind clinical polysomnography study. Int J Neurosci. 2009;119:2196\u2013205.","journal-title":"Int J Neurosci."},{"key":"730_CR70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","volume":"27","author":"L Morgante","year":"2004","unstructured":"Morgante L et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153\u20136.","journal-title":"Clin Neuropharmacol."},{"key":"730_CR71","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"KE Vanover","year":"2006","unstructured":"Vanover KE et al. Pharmacological and behavioral profile of N-(4-fl uorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2019-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006;317:910\u201318.","journal-title":"J Pharmacol Exp Ther"},{"key":"730_CR72","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1517\/14656560802532707","volume":"9","author":"A Abbas","year":"2008","unstructured":"Abbas A, Roth BL. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmatother. 2008;9:3251\u20139.","journal-title":"Expert Opin Pharmatother."},{"key":"730_CR73","doi-asserted-by":"crossref","unstructured":"Cummings J et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis; a randomised placebo-controlled phase 3 trial. Lancet. 2014;383:533\u201340. This is the randomized controlled trial of pimavanserin, the first FDA-approved drug for the specific indication of Parkinson\u2019s psychosis.","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"730_CR74","unstructured":"U.S. food and Drug Administration. www.accessdata.fda.gov\/drugsatfda_docs\/nda . Accessed February 2016."},{"key":"730_CR75","unstructured":"U.S. Food and Drug Administration. www.accessdata.fda.gov\/drugsatfda . Accessed 25th July 2016."},{"key":"730_CR76","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","volume":"27","author":"HH Fernandez","year":"2004","unstructured":"Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004;27:4\u20135.","journal-title":"Clin Neuropharmacol."},{"key":"730_CR77","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","volume":"21","author":"JH Friedman","year":"2006","unstructured":"Friedman JH et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson\u2019s disease. Mov Disord. 2006;21:2078\u2013208.","journal-title":"Mov Disord."},{"key":"730_CR78","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry. 2002;52:438\u201345.","journal-title":"Biol Psychiatry."},{"key":"730_CR79","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","volume":"17","author":"WG Ondo","year":"2002","unstructured":"Ondo WG et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031\u20135.","journal-title":"Mov Disord."},{"issue":"3","key":"730_CR80","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/jnp.12.3.364","volume":"12","author":"T Ellis","year":"2000","unstructured":"Ellis T et al. Clozapine and risperidone treatment of psychosis in Parkinson\u2019s disease. J Neuropsychiatr Clin Neurosci. 2000;12(3):364\u20139.","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"730_CR81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G Fabbrini","year":"2002","unstructured":"Fabbrini G et al. Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease. Neurol Sci. 2002;23:41\u20133.","journal-title":"Neurol Sci."},{"key":"730_CR82","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0891988703256054","volume":"16","author":"A Kurita","year":"2003","unstructured":"Kurita A et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson\u2019s disease. J Geriatr Psychiatry Neurol. 2003;16:184\u20138.","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"730_CR83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","volume":"25","author":"J Bergman","year":"2002","unstructured":"Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson\u2019s disease. Clin Neuropharmacol. 2002;25:107\u201310.","journal-title":"Clin Neuropharmacol."},{"key":"730_CR84","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","volume":"16","author":"PJ Reading","year":"2001","unstructured":"Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16:1171\u20134.","journal-title":"Mov Disord."},{"key":"730_CR85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF03074779","volume":"37","author":"JM Rovers","year":"2006","unstructured":"Rovers JM, Dautzenberg PL, ter Bruggen JP. Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease. Tijdschr Gerontol Geriatr. 2006;37:117\u201320.","journal-title":"Tijdschr Gerontol Geriatr"},{"key":"730_CR86","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","volume":"21","author":"D Burn","year":"2006","unstructured":"Burn D et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord. 2006;21:1899\u2013907.","journal-title":"Mov Disord"},{"key":"730_CR87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pnpbp.2006.06.016","volume":"31","author":"G Meco","year":"2007","unstructured":"Meco G, Bernadi S. Antidepressant use in treatment of psychosis with comorbid depression n Parkinson\u2019s disease. Prof Neuropsychopharmacol Biol Psychiatry. 2007;31:311\u20133.","journal-title":"Prof Neuropsychopharmacol Biol Psychiatry."},{"key":"730_CR88","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.yct.0000159325.08303.45","volume":"21","author":"F Ozer","year":"2005","unstructured":"Ozer F et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT. 2005;21:125\u20137.","journal-title":"J ECT"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-016-0730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-016-0730-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-016-0730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T22:44:50Z","timestamp":1498344290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-016-0730-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,14]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s11920-016-0730-1","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,14]]},"article-number":"97"}}